Results 21 to 30 of about 32,649 (166)

Construction and evaluation of wild and mutant ofatumumab scFvs against the human CD20 antigen

Preparative Biochemistry & Biotechnology, 2022
Several monoclonal antibodies targeting the CD20 have been produced and Ofatumumab is a case in point. Although whole antibodies target cancer cells effectively, their applications are restricted in some ways. Single-chain fragment variable antibodies, rather than employing the entire structure of antibodies, have proven a practical approach for ...
Reza Maleki, Azam Rahimpour, Masoumeh Rajabibazl   +2 more
openaire   +2 more sources

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

EBioMedicine, 2020
Background: DuoBody®-CD3xCD20 (GEN3013) is a full-length human IgG1 bispecific antibody (bsAb) recognizing CD3 and CD20, generated by controlled Fab-arm exchange. Its Fc domain was silenced by introduction of mutations L234F L235E D265A.
Patrick J. Engelberts, Ida H. Hiemstra, Bart de Jong, Danita H. Schuurhuis, Joyce Meesters, Irati Beltran Hernandez, Simone C. Oostindie, Joost Neijssen, Edward N. van den Brink, G. Jean Horbach, Sandra Verploegen, Aran F. Labrijn, Theodora Salcedo, Janine Schuurman, Paul W.H.I Parren, Esther C.W. Breij   +15 more
doaj   +1 more source

Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions [PDF]

Journal of Immunotherapy, 2018
Chimeric antigen receptor (CAR)-based adoptive T-cell therapy is a highly promising treatment for lymphoid malignancies, and CD20 is an ideal target antigen. We previously developed a lentiviral construct encoding a third generation CD20-targeted CAR but identified several features that required additional optimization before clinical translation.
Sang Yun, Lee, Philip, Olsen, Dong Hoon, Lee, Aimee L, Kenoyer, Lihua E, Budde, Shyril, O'Steen, Damian J, Green, Shelly, Heimfeld, Michael C, Jensen, Stanley R, Riddell, Oliver W, Press, Brian G, Till   +11 more
openaire   +2 more sources

CYTOTOXIC LYMPHOCYTES: THE ROLE IN INFLAMMATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION AND REMISSION

Alʹmanah Kliničeskoj Mediciny, 2016
Background: Despite the number of publications related to the expression of surface antigens of periphery blood lymphocytes in chronic obstructive pulmonary disease (COPD), algorithm for interpreting of the results and implicating pathogene-tic ...
N. A. Raspopina, E. G. Shuganov, F. N. Paleev, Zh. M. Salmasi, A. E. Shuganov   +4 more
doaj   +1 more source

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Journal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung, Nattiya Hirankarn, Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Alexander McLellan, Koramit Suppipat   +6 more
doaj   +1 more source

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Journal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang, Caili Zhang, Yingchun Zhang, Yuting Fan, Jing Zhang, Xiaojin Lin, Ting Guo, Yangzuo Gu, Jieheng Wu, Jianmei Gao, Xing Zhao, Zhixu He   +11 more
doaj   +1 more source

Anti-CD20 Immunoglobulin G Radiolabeling with a 99mTc-Tricarbonyl Core: In Vitro and In Vivo Evaluations. [PDF]

PLoS ONE, 2015
In recent years, the diagnostic and therapeutic uses of radioisotopes have shown significant progress. Immunoglobulin (Ig) appears to be a promising tracer, particularly due to its ability to target selected antigens.
Hélène Carpenet, Armelle Cuvillier, Jacques Monteil, Isabelle Quelven   +3 more
doaj   +1 more source

An oncolytic measles virus engineered to enter cells through the CD20 antigen

Molecular Therapy, 2003
We have earlier shown that attenuated measles virus (MV) has therapeutic potential as a replicating oncolytic virus in models of non-Hodgkin's lymphoma (NHL). In the current study, we investigated whether we could obtain replicating MVs capable of entering CD20(+) target cells through an interaction between a single-chain (scFv) anti-CD20 antibody and ...
Bucheit, Amanda D, Kumar, Shaji, Grote, Deanna M, Lin, Yukang, von Messling, Veronika, Cattaneo, Roberto B, Fielding, Adele K   +6 more
openaire   +2 more sources

CD20-positive peripheral T-cell lymphoma not otherwise specified: a case series and review of the literature

Frontiers in Oncology
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous and aggressive malignancy that usually lacks B-cell associated antigens.
Pan Zhou, Lifu Wang, Xiaohang Pei, Liu Yang, Yunmeng Zhou, Rongjun Ma, Yuqing Chen, Zunmin Zhu, Xiaoli Yuan   +8 more
doaj   +1 more source

The Influence of B Cell Depletion Therapy on Naturally Acquired Immunity to Streptococcus pneumoniae

Frontiers in Immunology, 2021
The anti-CD20 antibody Rituximab to deplete CD20+ B cells is an effective treatment for rheumatoid arthritis and B cell malignancies, but is associated with an increased incidence of respiratory infections.
Giuseppe Ercoli, Elisa Ramos-Sevillano, Rie Nakajima, Rafael Ramiro de Assis, Algis Jasinskas, David Goldblatt, Philip Felgner, Gisbert Weckbecker, Jeremy Brown   +8 more
doaj   +1 more source